Brief: Active Biotech's Patent For Laquinimod In Eye Disorders To Be Granted In US
13/11/2024 07:34
Nov 13 (Reuters) - Active Biotech AB publ ACTI.ST :
* PATENT FOR LAQUINIMOD IN EYE DISORDERS WILL BE GRANTED IN
THE US
* PATENT PROVIDES PROTECTION AND MARKET EXCLUSIVITY UNTIL
2040
Source text: ID:nMFN9BkNvz
Further company coverage: ACTI.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Active Biotech AB publ
See all newsBrief: Active Biotech Says Japan Grants Patent For Laquinimod Ophthalmic Formulation
Brief: Active Biotech Reports Q2 Operating Profit Of SEK -10.2 Mln
Brief: Active Biotech Expands U.S. Collaboration
Brief: Active Biotech Gets Approval To Resume Enrolment In Hovon 172 MF Study
Brief: Active Biotech Q1 Loss After Tax At SEK 8.4 Million